Sandbox leucocytosis: Difference between revisions
No edit summary |
Aditya Ganti (talk | contribs) No edit summary |
||
Line 118: | Line 118: | ||
*Can spread to [[TMJ]] | *Can spread to [[TMJ]] | ||
*Some times associated with [[leukoplakia]] | *Some times associated with [[leukoplakia]] | ||
|[[File:PLoS oral cancer.png|thumb|400x400px | |[[File:PLoS oral cancer.png|thumb|400x400px|Squamous cell carcinoma - By Luca Pastore, Maria Luisa Fiorella, Raffaele Fiorella, Lorenzo Lo Muzio - http://www.plosmedicine.org/article/showImageLarge.action?uri=info%3Adoi%2F10.1371%2Fjournal.pmed.0050212.g001, CC BY 2.5, https://commons.wikimedia.org/w/index.php?curid=15252632]] | ||
|- | |- | ||
|[[Leukoplakia]] | |[[Leukoplakia]] | ||
Line 139: | Line 139: | ||
*Persistant white spots | *Persistant white spots | ||
*[[Benign]] but can progress to [[carcinoma]] after almost 10 years | *[[Benign]] but can progress to [[carcinoma]] after almost 10 years | ||
*Oral proliferative [[Leukoplakia|verrucous leukoplakia]] is an aggressive sub type with multiple lesions and higher conversion to [[warts]] or [[carcinoma]] | *Oral proliferative [[Leukoplakia|verrucous leukoplakia]] is an aggressive sub type with multiple lesions and higher conversion to [[warts]] or [[carcinoma]] | ||
|[[File:Oral hairy leukoplakia (EBV, in HIV)a.jpg|thumb|400x300px|Leukoplakia - By Aitor III - Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=9873087]] | |[[File:Oral hairy leukoplakia (EBV, in HIV)a.jpg|thumb|400x300px|Leukoplakia - By Aitor III - Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=9873087]] | ||
|- | |- | ||
Line 329: | Line 318: | ||
*[[Sore throat]] | *[[Sore throat]] | ||
| | | | ||
*[[Medications]] | *[[Medications]] | ||
*[[List of chemotherapeutic agents#Cytotoxic Chemotherapy|Cytotoxic chemotherapy]] | *[[List of chemotherapeutic agents#Cytotoxic Chemotherapy|Cytotoxic chemotherapy]] | ||
*[[Hematological malignancy|Hematologic malignancies]] | *[[Hematological malignancy|Hematologic malignancies]] | ||
Line 351: | Line 340: | ||
| | | | ||
|- | |- | ||
|[[Syphilis]] | |[[Syphilis]] | ||
| | | | ||
*[[Chancre]] | *[[Chancre]] | ||
Line 409: | Line 398: | ||
| | | | ||
*Symptomatic treatment | *Symptomatic treatment | ||
|[[File:Hand foot mouth disease 07a.jpg|thumb|400x400px|Hand-foot-and-mouth disease - adapted from atlasdermatologico.com | |[[File:Hand foot mouth disease 07a.jpg|thumb|400x400px|Hand-foot-and-mouth disease - adapted from atlasdermatologico.com]] | ||
|- | |- | ||
|[[Chickenpox|Chicken pox]] | |[[Chickenpox|Chicken pox]] | ||
Line 445: | Line 433: | ||
*[[Koplick spots]] in mouth | *[[Koplick spots]] in mouth | ||
| | | | ||
*Unvaccinated individuals | *Unvaccinated individuals | ||
*Crowded and/or unsanitary conditions | *Crowded and/or unsanitary conditions | ||
*Traveling to less developed and developing countries | *Traveling to less developed and developing countries | ||
Line 471: | Line 459: | ||
|- | |- | ||
! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions | ! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions | ||
! | |||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
| colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | | colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ||
Line 478: | Line 467: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoedema | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoedema | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 485: | Line 475: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fordyce granules | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Fordyce granules | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 520: | Line 483: | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ||
Line 527: | Line 491: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyogenic granuloma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyogenic granuloma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 534: | Line 499: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral ossifying fibroma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral ossifying fibroma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 541: | Line 507: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Granular cell tumor | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Granular cell tumor | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 548: | Line 515: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral giant cell granuloma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral giant cell granuloma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 555: | Line 523: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral hemangioma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral hemangioma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 562: | Line 531: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Palisaded encapsulated neuroma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Palisaded encapsulated neuroma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 569: | Line 539: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Neurofibroma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Neurofibroma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 576: | Line 547: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Neodymium-doped yttrium alluminium garnet | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Neodymium-doped yttrium alluminium garnet | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 583: | Line 555: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pigmented lesions | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pigmented lesions | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 590: | Line 563: | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ||
Line 597: | Line 571: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoplakia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoplakia | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 604: | Line 579: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral proliferative verrucous leukoplakia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral proliferative verrucous leukoplakia | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 611: | Line 587: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Erythroplakia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Erythroplakia | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 618: | Line 595: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral submucus fibrosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral submucus fibrosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 625: | Line 603: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral lichen planus and lichenoid lesions | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral lichen planus and lichenoid lesions | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 632: | Line 611: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral discoid lupus erythmatosus | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral discoid lupus erythmatosus | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 639: | Line 619: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral chronic graft vs host disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral chronic graft vs host disease | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 646: | Line 627: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Actinic chelitis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Actinic chelitis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 653: | Line 635: | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnostic procedure | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Epithelial tissue origin | * Epithelial tissue origin | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 673: | Line 650: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Nerve tissue origin | * Nerve tissue origin | ||
** Malignant schwannoma | ** Malignant schwannoma | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 696: | Line 707: | ||
** Leiomyosarcoma | ** Leiomyosarcoma | ||
** Rhabdomyosarcoma | ** Rhabdomyosarcoma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 712: | Line 724: | ||
*** Multiple myeloma | *** Multiple myeloma | ||
*** Plasmacytoma | *** Plasmacytoma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 722: | Line 735: | ||
** Firbrosarcoma | ** Firbrosarcoma | ||
** Liposarcoma | ** Liposarcoma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 736: | Line 750: | ||
** Kaposi sarcoma | ** Kaposi sarcoma | ||
** Ewing's sarcoma | ** Ewing's sarcoma | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,276: | Line 1,291: | ||
*Melan-A or anti-tyrosinase | *Melan-A or anti-tyrosinase | ||
|} | |} | ||
<references /> |
Revision as of 16:45, 23 January 2019
Disease | Presentation | Risk Factors | Diagnosis | Affected Organ Systems | Important features | Picture |
---|---|---|---|---|---|---|
Diseases predominantly affecting the oral cavity | ||||||
Oral Candidiasis |
|
|
|
Localized candidiasis
Invasive candidasis |
|
|
Herpes simplex oral lesions |
|
|
|
|
||
Aphthous ulcers |
|
|
|
|
|
|
Squamous cell carcinoma |
|
|
||||
Leukoplakia |
|
|
|
|
||
Melanoma |
|
|
|
|
||
Fordyce spots |
|
|
|
|
||
Burning mouth syndrome |
|
|
||||
Torus palatinus |
|
|||||
Diseases involving oral cavity and other organ systems | ||||||
Behcet's disease |
|
|
|
|||
Crohn's disease |
|
|
|
|||
Agranulocytosis |
|
|
||||
Syphilis |
|
|
|
|||
Coxsackie virus |
|
|
||||
Chicken pox |
|
|
|
|
||
Measles |
|
|
|
|
Normal variant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
---|---|---|---|---|---|---|
Leukoedema | ||||||
Fordyce granules | ||||||
Benign Oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
Pyogenic granuloma | ||||||
Peripheral ossifying fibroma | ||||||
Granular cell tumor | ||||||
Peripheral giant cell granuloma | ||||||
Oral hemangioma | ||||||
Palisaded encapsulated neuroma | ||||||
Neurofibroma | ||||||
Neodymium-doped yttrium alluminium garnet | ||||||
Pigmented lesions | ||||||
Pre-malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
Leukoplakia | ||||||
Oral proliferative verrucous leukoplakia | ||||||
Erythroplakia | ||||||
Oral submucus fibrosis | ||||||
Oral lichen planus and lichenoid lesions | ||||||
Oral discoid lupus erythmatosus | ||||||
Oral chronic graft vs host disease | ||||||
Actinic chelitis | ||||||
Malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
|
Type of cancer | Subtype | Epidemiology | Localization | Clinical features | Diagnostic procedures |
---|---|---|---|---|---|
Squamous cell carcinoma
|
Verrucous carcinoma |
|
|
|
Biopsy shows:
Thickened club-shaped papillae and blunt stromal invaginations of well-differentiated squamous epithelium with marked keratinization |
Lymphoepithelial carcinoma | 0.8-2% of all oral or oropharyngeal cancers |
|
|
Biopsy chows:
| |
Epithelial precursor lesions | --- | --- | Seen in the entire digestive tract |
|
Biopsy shows:
|
Proliferative verrucous leukoplakia and precancerous conditions | --- |
|
|
An aggressive form of oral leukoplakia with considerable morbidity and
strong predilection to malignant transformation |
Biopsy shows:
|
Papillomas | Squamous cell papilloma and |
|
Any oral site may be affected mostly:
|
Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface | Biopsy shows:
|
Condyloma acuminatum | 2nd and 5th decade with a peak in teenagers and young adults |
|
Biopsy shows:
Several sessile, cauliflower-like swellings forming a cluster | ||
Focal epithelial hyperplasia | Disease of children, adolescents and young adults |
|
|
Biopsy shows:
| |
Granular cell tumor | --- |
|
|
|
Biopsy shows:
|
Keratoacanthoma | --- |
whites
men as in women |
|
|
Biopsy shows:
|
Papillary hyperplasia | --- | Affects all age groups | Palate | Asymptomatic nodular or papillary mucosal lesion | Biopsy shows:
|
Median rhomboid glossitis | --- | --- | Dorsum of the tongue at the junction of the anterior two thirds
and posterior third |
Forms a patch of papillary atrophy in the region of the
embryological foramen caecum |
Biopsy shows:
|
Salivary gland tumors | Acinic cell carcinoma |
|
Tumors usually
form non-descript swellings |
Biopsy shows:
| |
Mucoepidermoid carcinoma |
|
|
|
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma | |
Adenoid cystic carcinoma |
|
|
Predominantly solid variant shows peri- and intraneural invasion | ||
Epithelial-myoepithelial
carcinoma |
--- | --- | --- | --- | |
Clear cell carcinoma,
NOS |
--- | --- | --- | ||
Basal cell | Rare in minor glands | Asymptomatic, smooth or lobulated sub-mucosal masses | Microscopically similar to basal
cell adenocarcinomas of the major gland | ||
Cystadenocarcinoma | 32% developed in the minor glands |
|
Slow growing and painless but
some palatal tumors may erode the underlying bone causing sinonasal complex |
--- | |
Salivary duct carcinoma |
|
|
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes | The range of
microscopical appearances is similar to that seen in the major glands | |
Salivary gland adenomas | Pleomorphic adenoma | 40-70% of minor gland tumors |
|
Painless, slow growing, submucosal masses, but when | Biopsy shows cellular, and hyaline or plasmacytoid cell |
Myoepithelioma | 42% of minor gland tumors |
|
--- | --- | |
Basal cell adenoma | 20% of minor gland tumors | --- | They are histologically
similar to those in major glands. | ||
Cystadenoma | 7% of benign minor gland tumors | --- | --- | ||
Kaposi sarcoma | --- |
|
|
Biopsy of all 4 types show:
| |
Lymphangioma | --- |
|
Tongue |
|
Biopsy shows:
|
Ectomesenchymal chondromyxoid
tumour of the anterior tongue |
--- |
|
--- | Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue | Biopsy shows:
|
Focal oral mucinosis (FOM) | --- |
|
Asymptomatic fibrous or cystic-like lesion | Histopathology is characterized by:
| |
Congenital granular cell epuli | --- |
|
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar
ridge near the midline |
||
Hematolymphoid tumors | Non-Hodgkin lymphoma | Second most common cancer of the oral cavity |
|
NHL of the lip presents with:
|
Biopsy shows:
|
Langerhans cell histiocytosis | --- |
and |
Common oral symptoms
include:
|
Biopsy shows ovoid Langerhans cells
with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm | |
Hodgkin lymphoma | --- |
|
Most patients present with localized disease (stage I/II), with
|
--- | |
Extramedullary myeloid
sarcoma |
--- | Isolated tumor-forming intraoral mass | Biopsy shows an Indian-file pattern of infiltration | ||
Follicular dendritic cell
sarcoma / tumour |
|
|
The patients usually
present with a painless mass |
Biopsy usually exhibits
borders and comprises:
| |
Mucosal malignant melanoma | --- |
|
80% arise:
Others:
|
|
|